Literature DB >> 19365633

Primary antiphospholipid syndrome presenting as hyponatremic hypertensive syndrome and acute adrenal insufficiency following it: a rare case.

Neslihan Kurtulmus1, Mehmet Ali Cikrikcioglu, Oyku Aksoy, Tufan Tukek.   

Abstract

Hyponatremic hypertensive syndrome (HHS) is rare and is characterized with hypertension together with hyponatremia, hypokalemia and low plasma osmolarity and considered to be based on renal ischemia. It can rarely develop due to antiphospholipid syndrome (APS). We reported a case of 43-year-old man with unilateral renal artery stenosis due to primary APS. He presented with a hypertensive hyponatremic episode. First, he was treated with antihypertensive drugs. Further, radiological imaging showed enlargement of bilaterally adrenal glands that mimic adrenal masses. Unilateral nephrectomy and adrenalectomy were performed. Pathological examination revealed necrosis in the adrenal tissue and thrombosis in its artery. After operation, acute adrenal insufficiency developed in the patient because of hemorrhagic infarction of bilaterally adrenal glands. He improved after intravenous hydrocortisone treatment. His therapy was maintained with oral prednisolone and fludrocortisone. This patient with HHS, due to primary APS, is the first case in literature and acute adrenal insufficiency is a rare complication of APS.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19365633     DOI: 10.1007/s00296-009-0922-7

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  16 in total

1.  Sufficient evidence to consider hydroxychloroquine as an adjunct therapy in antiphospholipid antibody (Hughes') syndome.

Authors:  Kam Hon Yoon
Journal:  J Rheumatol       Date:  2002-07       Impact factor: 4.666

2.  A "primary" antiphospholipid syndrome?

Authors:  R A Asherson
Journal:  J Rheumatol       Date:  1988-12       Impact factor: 4.666

3.  Hyponatremic-hypertensive syndrome with renal ischemia: an underrecognized disorder.

Authors:  M Agarwal; K L Lynn; A M Richards; M G Nicholls
Journal:  Hypertension       Date:  1999-04       Impact factor: 10.190

4.  [Non-ischemic neurological manifestations in patients with primary antiphospholipid syndrome].

Authors:  L A Kalashnikova
Journal:  Zh Nevrol Psikhiatr Im S S Korsakova       Date:  2005

Review 5.  Kidney disease in antiphospholipid syndrome.

Authors:  Mary-Carmen Amigo
Journal:  Rheum Dis Clin North Am       Date:  2006-08       Impact factor: 2.670

Review 6.  Clinical aspects and pathophysiology of diuretic-induced hyponatremia.

Authors:  M Abramow; E Cogan
Journal:  Adv Nephrol Necker Hosp       Date:  1984

7.  The "primary" antiphospholipid syndrome: major clinical and serological features.

Authors:  R A Asherson; M A Khamashta; J Ordi-Ros; R H Derksen; S J Machin; J Barquinero; H H Outt; E N Harris; M Vilardell-Torres; G R Hughes
Journal:  Medicine (Baltimore)       Date:  1989-11       Impact factor: 1.889

Review 8.  Adrenal involvement in the antiphospholipid syndrome: clinical and immunologic characteristics of 86 patients.

Authors:  Gerard Espinosa; Eugénia Santos; Ricard Cervera; Jean-Charles Piette; Gloria de la Red; Víctor Gil; Josep Font; Robert Couch; Miguel Ingelmo; Ronald A Asherson
Journal:  Medicine (Baltimore)       Date:  2003-03       Impact factor: 1.889

9.  Hyponatremic hypertensive syndrome and massive proteinuria in a patient with renin-producing leiomyosarcoma.

Authors:  R Misiani; A Sonzogni; E M Poletti; G Cassinelli; L Gualandris; S Pericotti; R Ghislandi; R Agazzi; M F Belair; P Bruneval
Journal:  Am J Kidney Dis       Date:  1994-07       Impact factor: 8.860

10.  Recurrent deep vein thrombosis and Addison's disease in "primary" antiphospholipid syndrome.

Authors:  R A Asherson; G R Hughes
Journal:  J Rheumatol       Date:  1989-03       Impact factor: 4.666

View more
  1 in total

1.  Thrombotic renal and adrenal manifestations of primary antiphospholipid syndrome.

Authors:  Lama Bazzi; Ali T Taher; Khaled M Musallam; Zeinab Saleh; Karim Z Masrouha; Imad Uthman
Journal:  Rheumatol Int       Date:  2009-08-22       Impact factor: 2.631

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.